<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286324</url>
  </required_header>
  <id_info>
    <org_study_id>101,749</org_study_id>
    <nct_id>NCT01286324</nct_id>
  </id_info>
  <brief_title>Chamomile for Chronic Primary Insomnia</brief_title>
  <official_title>A Pilot Grant to Examine the Feasibility, Efficacy and Tolerability of a Standardized Chamomile Extract in Treating Chronic Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an herb called chamomile can help to treat
      insomnia (difficulty in going to sleep or getting enough sleep) by increasing the amount of
      time that you sleep and/or improving the quality of your sleep. The study will also be
      looking at the effect of chamomile on day time fatigue and functioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia, defined as the inability to initiate or maintain sleep or lack of restorative
      sleep, is the most prevalent sleep complaint in primary care. Insomnia is associated with
      decreased quality of life, work limitations and increased healthcare utilization. Currently
      there is no treatment for chronic insomnia that is readily available, affordable, without
      significant side-effects and demonstrated to be safe for long term use. Consequently,
      treatments that would fill this gap are needed.

      Chamomile (Matricaria recutita) has been used as a gentle sleep agent by herbalists for
      several hundred years. It has been studied in animals for its sedative potential and shows
      promise for treating insomnia. Currently, chamomile's sedative mechanisms of action are
      unknown, but are thought to be through the major inhibitory neurotransmitter in the central
      nervous system, γ - aminobutyric acid (GABA). However, no study has examined chamomile's
      efficacy and safety for treating insomnia.

      The investigators propose a double-blind, placebo-controlled, randomized trial of chamomile
      in primary care patients with chronic insomnia. Thirty-four patients will be randomized to
      either Chamomile High Grade Extract, three 5 mg tablets standardized to 0.4% (-)-α-bisabolol
      twice daily or placebo and will be followed for 28 days for changes in a sleep diary (sleep
      efficiency, total sleep time, sleep-onset latency and sleep quality), insomnia severity and
      sleep disturbances. Secondary endpoints include assessing changes in day time functioning
      (measures of global quality of life, depression and anxiety) and monitoring for any signs of
      toxicity. The investigators will also determine the feasibility of conducting a larger trial
      with this agent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28.</measure>
    <time_frame>baseline and day 28</time_frame>
    <description>Change from baseline of chamomile extract, three tablets (equivalent to 7.5 g of dried herb) p.o. twice times daily versus placebo on the following sleep measures at 28 days:
the change from baseline of daily self-report of sleep as assessed by a sleep diary that includes determination of: (i) sleep efficiency, which equals &quot;The total sleep time divided by time-in-bed, multiplied by 100.&quot; This measure is our primary aim (SE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Chamomile on Daytime Functioning Measures: BDI</measure>
    <time_frame>baseline and day 28</time_frame>
    <description>Change from baseline of chamomile extract, three tablets p.o. twice times daily versus placebo on daytime functioning measures at 28 days:
the change from baseline of measures of depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II), which is scored on a scale of 0 to 63 where a total score of 0-13 is considered minimal range (minimal depression), 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Chamomile on Daytime Functioning Measures: STAI</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change From Baseline of Chamomile on Daytime Functioning Measures, depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II) and trait portrait of the State Trait Anxiety Index (STAI). STAI scores range for each subtest from 20-80, the higher score indicating greater anxiety. A cut point of 39-40 has been suggested to detect clinically significant symptoms for the S-Anxiety scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale (FSS) Range: 9 to 63. The 9-item scale measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders.
The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Chamomile on Daytime Functioning Measures [ Time Frame: Baseline and Day 28 ]</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>the change from baseline of global QOL (as determined by the 12 Item Short Form Health Survey Version 2 {SF-12 V2})</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in the Safety and Tolerability of Chamomile</measure>
    <time_frame>once per week during study and day 28</time_frame>
    <description>Changes from baseline in the safety and tolerability of Chamomile High Grade Extract, three tablets (equivalent to 7.5g of dried herb) p.o. twice times daily versus placebo were measured by counting all participants who reported a serious or non-serious adverse event at the weekly check-ins that were established.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Primary Insomnia</condition>
  <condition>Chronic Insomnia</condition>
  <arm_group>
    <arm_group_label>Chamomile High Grade Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Contained lactose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chamomile High Grade Extract</intervention_name>
    <description>three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days</description>
    <arm_group_label>Chamomile High Grade Extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <arm_group_label>Placebo Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 to 64 years;

          -  Must be able to give written informed consent;

          -  Have a diagnosis of primary insomnia per DSM-IV criteria, reporting &lt; 6.5 hours sleep
             and/or &gt;30 minutes to fall asleep (SOL) and/or wake after sleep onset (WASO) &gt; 30
             minutes, three or more nights per week;

          -  Present sleep complaint for at least 6 months;

        Exclusion Criteria:

          -  Women who are pregnant, lactating or less than six months post-partum. Due to the fact
             that an assessment of reproductive performance and teratology tests have not been
             conducted we are excluding pregnant and lactating women;

          -  Patients with unstable medical conditions;

          -  DSM-IV Axis I or personality disorder diagnosis with the exception of patients with
             treated and stable unipolar depression or generalized anxiety disorder (such that the
             PRIME-MD scores are within normal range for these disorders);

          -  Difficulty in sleep initiation or maintenance associated with known medical diagnosis
             or conditions that may affect sleep, e.g., sleep apnea, restless leg syndrome, chronic
             pain;

          -  Evidence of lack of reliability or noncompliance as defined by missing a pretreatment
             appointment more than twice;

          -  Current diagnosis of substance abuse or dependence;

          -  Known allergy to chamomile or members of the ragweed family;

          -  Currently taking cyclosporine, warfarin or chronic sedative and anxiolytic
             medications;

          -  Prior use of insomnia medications is not exclusionary, but patients must be off of
             these medications at the screening visit and through out the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanna M Zick, ND, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Todd Arnedt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Department of Family Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med. 2011 Sep 22;11:78. doi: 10.1186/1472-6882-11-78.</citation>
    <PMID>21939549</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <results_first_submitted>January 21, 2013</results_first_submitted>
  <results_first_submitted_qc>June 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Suzanna Zick</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Matricaria</keyword>
  <keyword>Chamomile</keyword>
  <keyword>Herb</keyword>
  <keyword>Insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Tablet</title>
          <description>Contained lactose</description>
        </group>
        <group group_id="P2">
          <title>Chamomile High Grade Extract</title>
          <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Tablet</title>
          <description>Contained lactose</description>
        </group>
        <group group_id="B2">
          <title>Chamomile High Grade Extract</title>
          <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="15.3"/>
                    <measurement group_id="B2" value="42.2" spread="13.5"/>
                    <measurement group_id="B3" value="41.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28.</title>
        <description>Change from baseline of chamomile extract, three tablets (equivalent to 7.5 g of dried herb) p.o. twice times daily versus placebo on the following sleep measures at 28 days:
the change from baseline of daily self-report of sleep as assessed by a sleep diary that includes determination of: (i) sleep efficiency, which equals &quot;The total sleep time divided by time-in-bed, multiplied by 100.&quot; This measure is our primary aim (SE).</description>
        <time_frame>baseline and day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28.</title>
          <description>Change from baseline of chamomile extract, three tablets (equivalent to 7.5 g of dried herb) p.o. twice times daily versus placebo on the following sleep measures at 28 days:
the change from baseline of daily self-report of sleep as assessed by a sleep diary that includes determination of: (i) sleep efficiency, which equals &quot;The total sleep time divided by time-in-bed, multiplied by 100.&quot; This measure is our primary aim (SE).</description>
          <units>percentage of time asleep</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="7.7"/>
                    <measurement group_id="O2" value="77.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <p_value_desc>Adjusted p-value based on a general linear model adjusted for group and the baseline of the measure</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Chamomile on Daytime Functioning Measures: BDI</title>
        <description>Change from baseline of chamomile extract, three tablets p.o. twice times daily versus placebo on daytime functioning measures at 28 days:
the change from baseline of measures of depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II), which is scored on a scale of 0 to 63 where a total score of 0–13 is considered minimal range (minimal depression), 14–19 is mild, 20–28 is moderate, and 29–63 is severe.</description>
        <time_frame>baseline and day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chamomile on Daytime Functioning Measures: BDI</title>
          <description>Change from baseline of chamomile extract, three tablets p.o. twice times daily versus placebo on daytime functioning measures at 28 days:
the change from baseline of measures of depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II), which is scored on a scale of 0 to 63 where a total score of 0–13 is considered minimal range (minimal depression), 14–19 is mild, 20–28 is moderate, and 29–63 is severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="6.0"/>
                    <measurement group_id="O2" value="3.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.0"/>
                    <measurement group_id="O2" value="2.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <p_value_desc>Adjusted p-value based on a general linear model adjusted for group and the baseline of the measure</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Chamomile on Daytime Functioning Measures: STAI</title>
        <description>Change From Baseline of Chamomile on Daytime Functioning Measures, depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II) and trait portrait of the State Trait Anxiety Index (STAI). STAI scores range for each subtest from 20–80, the higher score indicating greater anxiety. A cut point of 39–40 has been suggested to detect clinically significant symptoms for the S-Anxiety scale</description>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chamomile on Daytime Functioning Measures: STAI</title>
          <description>Change From Baseline of Chamomile on Daytime Functioning Measures, depression and anxiety evaluated respectively with the Beck Depression Inventory-II (BDI-II) and trait portrait of the State Trait Anxiety Index (STAI). STAI scores range for each subtest from 20–80, the higher score indicating greater anxiety. A cut point of 39–40 has been suggested to detect clinically significant symptoms for the S-Anxiety scale</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment State Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="9.7"/>
                    <measurement group_id="O2" value="30.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment State Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="11.0"/>
                    <measurement group_id="O2" value="30.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Treatment Trait Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="11.3"/>
                    <measurement group_id="O2" value="36.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment Trait Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="15.5"/>
                    <measurement group_id="O2" value="35.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis for State Subscale</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>Adjusted p-value based on a general linear model adjusted for group and the baseline of the measure</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value for Trait Subscale</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <p_value_desc>Adjusted p-value based on a general linear model adjusted for group and the baseline of the measure</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale</title>
        <description>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale (FSS) Range: 9 to 63. The 9-item scale measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders.
The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.</description>
        <time_frame>Baseline and 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale</title>
          <description>Change From Baseline of Chamomile on Daytime Functioning Measures: Fatigue Severity Scale (FSS) Range: 9 to 63. The 9-item scale measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders.
The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment FSS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" spread="9.1"/>
                    <measurement group_id="O2" value="32.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment FSS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="10.0"/>
                    <measurement group_id="O2" value="27.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>P value is adjusted based on a general linear model adjusted for group and the baseline of the measure</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Chamomile on Daytime Functioning Measures [ Time Frame: Baseline and Day 28 ]</title>
        <description>the change from baseline of global QOL (as determined by the 12 Item Short Form Health Survey Version 2 {SF-12 V2})</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Before first participants completed the study, the decision was made not to gather this data for reasons of cost.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Chamomile on Daytime Functioning Measures [ Time Frame: Baseline and Day 28 ]</title>
          <description>the change from baseline of global QOL (as determined by the 12 Item Short Form Health Survey Version 2 {SF-12 V2})</description>
          <population>Before first participants completed the study, the decision was made not to gather this data for reasons of cost.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in the Safety and Tolerability of Chamomile</title>
        <description>Changes from baseline in the safety and tolerability of Chamomile High Grade Extract, three tablets (equivalent to 7.5g of dried herb) p.o. twice times daily versus placebo were measured by counting all participants who reported a serious or non-serious adverse event at the weekly check-ins that were established.</description>
        <time_frame>once per week during study and day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Tablet</title>
            <description>Contained lactose</description>
          </group>
          <group group_id="O2">
            <title>Chamomile High Grade Extract</title>
            <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in the Safety and Tolerability of Chamomile</title>
          <description>Changes from baseline in the safety and tolerability of Chamomile High Grade Extract, three tablets (equivalent to 7.5g of dried herb) p.o. twice times daily versus placebo were measured by counting all participants who reported a serious or non-serious adverse event at the weekly check-ins that were established.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Tablet</title>
          <description>Contained lactose</description>
        </group>
        <group group_id="E2">
          <title>Chamomile High Grade Extract</title>
          <description>Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Used subjective sleep measures. We did not assess the characteristics of participants' sleep difficulties and these sleep issues may be important considering the age-range of individuals included in the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Suzanna M Zick</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-998-9553</phone>
      <email>szick@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

